Antitussive Agent

About: Antitussive Agent is a research topic. Over the lifetime, 380 publications have been published within this topic receiving 5776 citations.

Evaluation of antitussive potential of Ionidium suffruticosam Ging. (Violaceae) extract in albino mice.

Abstract: The present study was carried out to evaluate the antitussive potential of methanol extract of Ionidium suffruticosam Ging. (Violaceae) which was investigated for its effect on a cough model induced by sulfur dioxide gas in albino mice. It exhibited significant dose-dependent antitussive activity when compared with the control, 250 and 500 mg/kg (p.o.) of the extract showing 28.37% and 54.16% inhibition of the cough with respect to control group. The antitussive activity of the extract was comparable to that of codeine phosphate, a prototype antitussive agent.

Method of treating motion sickness with anticonvulsants and antitussive agents

Abstract: A method of treating or preventing motion sickness is disclosed which comprises administering an anti-motion sickness effective amount of an anticonvulsant compound such as phenytoin, ethotoin, primidone, ethosuximide or carbamazepine, in combination with a potentiating amount of an antitussive or cough suppressant agent such as dextromethorphan, levopropoxyphene, muscaphene, pholocodeine, or carbetapentene. The antitussive compounds of the present invention act as potentiating agents so as to enable effective treatment or prevention of motion sickness using a reduced amount of the anticonvulsant compound normally used in such treatment. The method of the present invention reduces the potential for various side effects and thus provides a safer and more effective method of treatment for motion sickness than prior art methods.

Novel pharmacological targets and progression of new antitussive drugs

Abstract: Cough is frequently associated with a wide array of respiratory infections, ailments and disorders. Consequently, cough is the number one symptomatic reason why people visit medical healthcare providers. Nonetheless, when cough-suppressant therapy is required by patients, many physicians are limited primarily to a single pharmacological class of antitussive agent, namely, opioids. Opioids, such as codeine, dominate the antitussive prescription market. These drugs act centrally within the CNS to attenuate cough due to a variety of causes. However, opioids often elicit significant receptor-related μopioid (MOP) untoward side effects such as constipation, respiratory depression, sedation, tolerance and addiction. The development of novel drugs that maintain or improve upon the antitussive efficacy of the opioids and do not possess MOP liabilities would represent a substantial improvement over currently available cough treatments. New antitussive pharmacological targets include non-MOP opioids, specifically, ...

Objective assessment of cough suppressants under normal and pathological experimental conditions.

Abstract: The influences of the antitussive activity of glaucine were studied in 56 non-anaesthetized cats under normal and pathological conditions. Cough was induced by mechanical stimulation of the airways with a nylon fibre. The authors found that if glaucine was administered at a dose of 5.0, 7.5 and 10.0 mg/kg b.w., i.p., it evoked statistically significant suppression on single cough components. After inflammation of the airways was induced with unsoluted croton oil, no decrease in antitussive activity of glaucine could be observed, according to the number of cough efforts, frequency, intensity of maximal cough effort, and intensity of cough attack during expiration. Glaucine used under such conditions was not found to be powerful enough to suppress either the intensity of maximal cough effort or the intensity of cough attack during inspiration. The antitussive effect of glaucine was stronger under pathological conditions (Staphylococcus-induced inflammation). The antitussive effect of glaucine was approximately the same as with codeine if administered in equal doses.